Interview by:
Produced by:
16 Apr 2018
Alexander Eggermont presents the results of KEYNOTE-054
Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, talks about the key findings of the KEYNOTE-054 trial and highlights pembrolizumab’s high therapeutic index.